MX2019007924A - Vacunas contra la influenza. - Google Patents

Vacunas contra la influenza.

Info

Publication number
MX2019007924A
MX2019007924A MX2019007924A MX2019007924A MX2019007924A MX 2019007924 A MX2019007924 A MX 2019007924A MX 2019007924 A MX2019007924 A MX 2019007924A MX 2019007924 A MX2019007924 A MX 2019007924A MX 2019007924 A MX2019007924 A MX 2019007924A
Authority
MX
Mexico
Prior art keywords
vaccines
influenza vaccines
influenza
based vaccines
methods
Prior art date
Application number
MX2019007924A
Other languages
English (en)
Spanish (es)
Inventor
Young Arthur
Sun Ren
C Wu Nicholas
Original Assignee
Invvax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invvax Inc filed Critical Invvax Inc
Publication of MX2019007924A publication Critical patent/MX2019007924A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2019007924A 2016-12-28 2017-12-28 Vacunas contra la influenza. MX2019007924A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662439865P 2016-12-28 2016-12-28
US201762550167P 2017-08-25 2017-08-25
PCT/US2017/068800 WO2018126060A1 (en) 2016-12-28 2017-12-28 Influenza vaccines

Publications (1)

Publication Number Publication Date
MX2019007924A true MX2019007924A (es) 2020-01-27

Family

ID=62710906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007924A MX2019007924A (es) 2016-12-28 2017-12-28 Vacunas contra la influenza.

Country Status (10)

Country Link
US (3) US11111277B2 (OSRAM)
EP (1) EP3562498A4 (OSRAM)
JP (1) JP2020515283A (OSRAM)
KR (1) KR20190129032A (OSRAM)
CN (1) CN111148528A (OSRAM)
AU (1) AU2017386682A1 (OSRAM)
BR (1) BR112019013402A2 (OSRAM)
CA (1) CA3048448A1 (OSRAM)
MX (1) MX2019007924A (OSRAM)
WO (1) WO2018126060A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019007924A (es) 2016-12-28 2020-01-27 Invvax Inc Vacunas contra la influenza.
KR20220047332A (ko) * 2019-08-13 2022-04-15 알티뮨 인크. 치료제 효과 및 이의 투여 경로
CN110772635B (zh) * 2019-11-11 2023-01-31 扬州大学 流感病毒小体包被的仿生纳米疫苗及其制备方法
WO2025214372A1 (zh) * 2024-04-08 2025-10-16 康希诺(上海)生物研发有限公司 一种流感mRNA疫苗及其制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1040001A (en) 1909-03-23 1912-10-01 Bofors Gullspaang Ab Breech-loading mechanism for artillery-guns.
US1017917A (en) 1910-12-17 1912-02-20 Joseph E Runner Combination block and tile machine.
US1023874A (en) 1911-10-12 1912-04-23 Thomas J Price Drinking-fountain.
US1042682A (en) 1912-04-17 1912-10-29 Okey J Jackson Toy cycle.
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
EP1690868A1 (en) 1997-10-31 2006-08-16 Maxygen, Inc. Modification of virus tropism and host range by viral genome shuffling
CA2323632A1 (en) 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
AU4441699A (en) 1998-06-17 2000-01-05 Maxygen, Inc. Method for producing polynucleotides with desired properties
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
AU5898400A (en) 1999-06-29 2001-01-31 Epimmune, Inc. Hla binding peptides and their uses
JP2003509035A (ja) * 1999-09-16 2003-03-11 ザイコス インク． ポリエピトープポリペプチドをコードする核酸
CN100412190C (zh) 2001-03-15 2008-08-20 复旦大学 乙肝病毒全基因组多聚酶嵌合体的组建方法和应用
JP2004532038A (ja) 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
WO2003009812A2 (en) 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
ES2369664T3 (es) 2002-08-12 2011-12-02 The Council Of The Queensland Institute Of Medical Research Lipopéptidos inmunogénicos novedosos que comprenden epítopos de células t cooperadoras y de células b.
EP1578432A4 (en) 2002-10-03 2008-07-30 Epimmune Inc HLA BINDING PEPTIDES AND USES THEREOF
ATE384789T1 (de) 2003-10-02 2008-02-15 Basf Ag Verfahren zur sequenz-saturations-mutagenese (sesam)
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
BRPI0518728A2 (pt) 2004-12-09 2008-12-02 Univ Pittsburgh vacinas para a resposta rÁpida À pandemia de gripe aviÁria
KR20080052509A (ko) 2005-04-11 2008-06-11 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 유행성 독감 바이러스에 대한 백신
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
EP1948227A4 (en) 2005-10-26 2010-03-31 Protelix Inc COMBINATORY ANTIGEN VACCINE AGAINST FLU
ATE552846T1 (de) 2005-12-06 2012-04-15 Yeda Res & Dev Verbesserter grippeimpfstoff
US20090023895A1 (en) 2006-02-07 2009-01-22 Nec Corporation Hla-binding peptide, precursor thereof, and dna fragment and recombinant vector coding for said hla-binding peptide
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
WO2008039267A2 (en) 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2009014919A2 (en) * 2007-07-13 2009-01-29 Iowa State University Research Foundation, Inc. H2n3 influenza a viruses and methods of use
PL2173376T3 (pl) 2007-08-02 2015-08-31 Biondvax Pharmaceuticals Ltd Multimeryczne wieloepitopowe szczepionki przeciwko grypie
EP2772267B1 (en) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
CN101575608A (zh) * 2008-05-07 2009-11-11 中国科学院上海生命科学研究院 针对禽流感病毒的重组联合dna疫苗
AU2009259964B2 (en) 2008-06-19 2015-04-09 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
AU2010278797A1 (en) * 2009-07-31 2012-03-15 Paxvax, Inc. Adenoviral-based vectors
AU2010300623A1 (en) 2009-09-30 2012-04-19 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses
WO2012082803A2 (en) 2010-12-13 2012-06-21 Cel-Sci Corporation Method for inducing an immune response against avian, swine, spanish, h1n1, h5n9 influenza viruses and formulations thereof
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US10179174B2 (en) * 2011-05-25 2019-01-15 Cel-Sci Corp. Method for inducing an immune response and formulations thereof
US9205144B2 (en) * 2011-06-03 2015-12-08 Dana-Farber Cancer Institute, Inc. Identification of conserved peptide blocks in homologous polypeptides
WO2013093512A2 (en) 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccine - screening method
KR101382244B1 (ko) 2012-03-30 2014-04-08 재단법인 목암생명공학연구소 광범위한 인플루엔자 바이러스의 감염을 방어할 수 있는 ｔ―세포 기반 유니버설 플루 백신
US20140274806A1 (en) * 2013-03-15 2014-09-18 Synthetic Genomics Vaccines Influenza virus reassortment
US10426828B2 (en) 2014-04-03 2019-10-01 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
WO2015157189A1 (en) 2014-04-07 2015-10-15 The Regents Of The University Of California Vaccines and uses thereof
GB201603568D0 (en) 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
JP7467027B2 (ja) 2016-05-03 2024-04-15 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 免疫刺激性ポリペプチドおよび抗原性ポリペプチドを含む酵母ワクチンベクター並びにそれを使用する方法
MX2019007924A (es) 2016-12-28 2020-01-27 Invvax Inc Vacunas contra la influenza.
US11517617B2 (en) 2017-09-08 2022-12-06 The University Of Melbourne Methods and compositions for preventing influenza infection

Also Published As

Publication number Publication date
US11739127B2 (en) 2023-08-29
CA3048448A1 (en) 2018-07-05
KR20190129032A (ko) 2019-11-19
US12234263B2 (en) 2025-02-25
US20230416311A1 (en) 2023-12-28
AU2017386682A1 (en) 2019-07-25
JP2020515283A (ja) 2020-05-28
BR112019013402A2 (pt) 2020-03-03
EP3562498A1 (en) 2019-11-06
WO2018126060A1 (en) 2018-07-05
US20220002352A1 (en) 2022-01-06
EP3562498A4 (en) 2020-10-28
US11111277B2 (en) 2021-09-07
US20180230187A1 (en) 2018-08-16
CN111148528A (zh) 2020-05-12

Similar Documents

Publication Publication Date Title
MX384992B (es) Combinaciones inmunógenas.
PH12017501287A1 (en) A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
EA201391515A1 (ru) Инактивированная вакцина вируса денге
MX387985B (es) Particulas tipo virus modificadas de cmv.
ZA202403393B (en) Synthetic chimeric poxviruses
EP4043031A3 (en) Zika viral antigen constructs
WO2015052543A3 (en) Malaria vaccination
EA201790239A1 (ru) Молекула-носитель для антигенов
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
PH12016500500A1 (en) A viral vaccine and methods of manufacture thereof
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
MX2019007924A (es) Vacunas contra la influenza.
HK1254522A1 (zh) 灭活的犬流感疫苗以及其制备方法和用途
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
PH12018501532A1 (en) Cancer vaccines